Baxter International Inc. (NYSE:BAX)‘s stock had its “hold” rating reiterated by Bank of America Corporation in a research note issued to investors on Wednesday.

A number of other equities research analysts have also weighed in on BAX. BidaskClub upgraded shares of Baxter International from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 14th. Citigroup Inc. assumed coverage on shares of Baxter International in a research note on Thursday, August 17th. They set a “neutral” rating and a $63.00 target price for the company. Royal Bank Of Canada reiterated a “hold” rating and set a $60.00 target price on shares of Baxter International in a research note on Tuesday, October 3rd. Cowen Inc set a $68.00 target price on shares of Baxter International and gave the company a “hold” rating in a research note on Sunday, October 15th. Finally, Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Seven analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $67.46.

Baxter International (NYSE BAX) opened at $64.04 on Wednesday. The stock has a market capitalization of $35,005.45, a P/E ratio of 26.55, a P/E/G ratio of 2.15 and a beta of 0.68. Baxter International has a 12-month low of $43.13 and a 12-month high of $65.70. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. The business had revenue of $2.71 billion for the quarter, compared to analysts’ expectations of $2.66 billion. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.56 EPS. equities analysts anticipate that Baxter International will post 2.43 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/baxter-international-inc-bax-stock-rating-reaffirmed-by-bank-of-america-corporation/1722783.html.

In other news, Director Thomas T. Stallkamp sold 8,920 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $62.28, for a total value of $555,537.60. Following the completion of the sale, the director now directly owns 16,263 shares in the company, valued at approximately $1,012,859.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Third Point Llc sold 5,000,000 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total value of $321,150,000.00. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Bessemer Group Inc. boosted its holdings in Baxter International by 42,907.2% in the 2nd quarter. Bessemer Group Inc. now owns 4,652,950 shares of the medical instruments supplier’s stock worth $281,690,000 after buying an additional 4,642,131 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Baxter International by 71.1% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,632,846 shares of the medical instruments supplier’s stock worth $98,852,000 after buying an additional 678,429 shares during the period. Canada Pension Plan Investment Board boosted its holdings in Baxter International by 35.8% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock worth $88,669,000 after buying an additional 372,500 shares during the period. New York State Common Retirement Fund boosted its holdings in Baxter International by 19.0% in the 2nd quarter. New York State Common Retirement Fund now owns 1,830,523 shares of the medical instruments supplier’s stock worth $110,820,000 after buying an additional 291,752 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its holdings in Baxter International by 209.0% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock worth $25,856,000 after buying an additional 278,685 shares during the period. Hedge funds and other institutional investors own 83.49% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.